Quest Global Receives Great Place To Work® Certification™ in the USA, Reflecting Its Dedication to a Positive Work Culture
WINDSOR, Conn., Feb. 27, 2025 /CNW/ -- Quest Global, a leading global product engineering services company, is proud to announce its certification as a Great Place To Work® in the USA. This is the second straight year that Quest Global has earned this recognition for the USA market. The organization has also received recognition for four consecutive years in India, from 2022 onwards.
Quest Global scored well on the five critical dimensions of Trust Index™ – credibility, respect, fairness, pride, and camaraderie. The company enjoyed strong results based on onboarding new employees, with 90 percent of respondents saying they felt welcome while joining the organization.
Commenting on the achievement, Sonia Kutty, Senior Vice President, Global Head - People & Culture, Quest Global, said, 'We are proud to be awarded the Great Place To Work® Certification™ for the second consecutive year in the USA. This is a glowing endorsement of our continuous efforts to build a healthy and happy work environment where our employees enjoy both professional and personal growth. Our workforce is at the heart of Quest Global's operations, and we are confident of sustaining the positive momentum we have built in the USA.'
Quest Global remains committed to promoting and sustaining a high-trust, high-performance culture, and guiding the firm towards strengthening its aim to be a centenary organization. The successful participation and vote of confidence in the assessment held across the organization by Great Place To Work® anonymously helped Quest Global benchmark the people practices in the USA.
Great Place To Work® Certification™ is the gold standard that organizations around the globe aspire to achieve. This recognition is a testament to the organization's consistent efforts to build and sustain a high-trust, high-performance culture. The global authority on workplace culture, the institute's research shows great workplaces are characterized by outstanding leadership, consistent employee experience, and sustainable financial performance. These organizations can deliver the same experience to all of their employees irrespective of their role, gender, tenure, or level.
About Quest Global
At Quest Global, it's not just what we do but how and why we do it that makes us different. We're in the business of engineering, but what we're really creating is a brighter future. For over 25 years, we've been solving the world's most complex engineering problems. Operating in over 20 countries, with over 85 global delivery centers, our 20,000+ curious minds embrace the power of doing things differently to make the impossible possible. Using a multi-dimensional approach, combining technology, industry expertise, and diverse talents, we tackle critical challenges faster and more effectively. And we do it across the Aerospace & Defense, Automotive, Energy, Hi-Tech, MedTech & Healthcare, Rail and Semiconductor industries. For world-class end-to-end engineering solutions, we are your trusted partner.
About Great Place To Work® Certification™
This Certification is the gold standard that organizations around the globe aspire to accomplish. Great Place To Work is the global authority on workplace culture. The institute's research shows that great workplaces are characterized by outstanding leadership, consistent employee experience, and sustainable financial performance. These organizations can deliver the same experience to all of their employees irrespective of their role, gender, tenure, or level within the organization.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.
Hamilton Spectator
2 days ago
- Hamilton Spectator
Jetoptera Executes FETT for FTC-250 at Paris Air Show 2025
PARIS, June 21, 2025 (GLOBE NEWSWIRE) — On the occasion of Jetoptera's debut at the Paris Air Show 2025, we are proud to announce the successful completion of the first test of the engine that will power the J-500, the 500-lb VTOL cargo unmanned aircraft system Jetoptera is developing in collaboration with Eanan Al Samma, for the United Arab Emirates (UAE) market. The First Engine To Test (FETT) was evaluated at the VAN DER LEE Turbo Systems facilities in Zaandam, The Netherlands. The 250 kW turbocompressor, that is the heart of the Fluidic Propulsive System™, is a two-shaft engine using a free turbine that is mechanically coupled to a two-stage axial compressor designed to produce the appropriate flow rates and pressure ratios required by the FPS™. 'The FETT demonstrated a very smooth startup and operability when operated in a turbofan mode. The engine was instrumented in this configuration, to monitor pressure and temperature as well as thrust produced. The next step includes the performance mapping of the turbocompressor, followed by the integration with the FPS™ onto the J-500 airframe,' said Dr Andrei Evulet, CEO/CTO of Jetoptera, Inc. The J-500 prototype is developed specifically for the UAE and MENA market and will be uniquely enabled by the FPS™ to perform unmanned cargo missions with VTOL and unmatched speed, low noise, and reliability thanks to the patented propulsion system. The modularity of the FTC-250 system allows its components to operate in turbojet, turbofan and FPS™ modes. Jetoptera and Eanan Al Samma thank Parametric Solutions, Inc. and VAN DER LEE Turbo Systems for their critical support in the design and manufacturing of the unique FTC-250 architecture in record time. For information about this press release please contact Todd Newton todd@ Jetoptera, Inc. Facebook: LinkedIn: A photo accompanying this announcement is available at
Associated Press
2 days ago
- Associated Press
Dolmen Achieves Historic 100% in Great Place to Work® 2025, Leading in Global Workplace Well-Being
Atlanta, GA June 20, 2025 --( )-- Dolmen Group., a Colombian multinational leader in urban infrastructure, has reached an unprecedented milestone by earning a 100% rating in the Great Place to Work® 2025 certification across Colombia, the United States, Mexico, and Peru. This recognition ranks Dolmen among the top 10 workplaces globally, highlighting its inclusive and innovative workplace culture, which also thrives in diverse markets such as Dubai, China, Panama and Portugal. With over 30 years of transforming cities through solutions like smart lighting and eco-efficient urban furniture, Dolmen celebrates this achievement, reflecting 100% employee satisfaction based on anonymous surveys. The company was also named one of the Best Places to Work for Women in Colombia 2025, reinforcing its commitment to gender equity. 'This 100% score is a source of pride and drives us to continue empowering our team while innovating for sustainable cities,' said Carlos Mario Peláez, CEO of Dolmen. The company plans to expand its workplace well-being model and technological solutions to new global markets in 2025. About Dolmen Group Founded in 1994 in Barranquilla, Colombia, Dolmen leads in urban furniture, public lighting, and traffic management, with a presence in 12 countries. Contact Information: Dolmen Eduardo cortes 786-830-5929 Contact via Email Read the full story here: Dolmen Achieves Historic 100% in Great Place to Work® 2025, Leading in Global Workplace Well-Being Press Release Distributed by
